MX2022007943A - Formas farmaceuticas solidas que contienen bacterias y vesiculas extracelulares microbianas. - Google Patents

Formas farmaceuticas solidas que contienen bacterias y vesiculas extracelulares microbianas.

Info

Publication number
MX2022007943A
MX2022007943A MX2022007943A MX2022007943A MX2022007943A MX 2022007943 A MX2022007943 A MX 2022007943A MX 2022007943 A MX2022007943 A MX 2022007943A MX 2022007943 A MX2022007943 A MX 2022007943A MX 2022007943 A MX2022007943 A MX 2022007943A
Authority
MX
Mexico
Prior art keywords
dosage forms
solid dosage
extracellular vesicles
forms containing
containing bacteria
Prior art date
Application number
MX2022007943A
Other languages
English (en)
Spanish (es)
Inventor
Brian Goodman
Syed Altaf
Christopher J H Davitt
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of MX2022007943A publication Critical patent/MX2022007943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022007943A 2019-12-27 2020-12-23 Formas farmaceuticas solidas que contienen bacterias y vesiculas extracelulares microbianas. MX2022007943A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962954153P 2019-12-27 2019-12-27
PCT/US2020/066828 WO2021133904A1 (en) 2019-12-27 2020-12-23 Solid dosage forms containing bacteria and microbial extracellular vesicles

Publications (1)

Publication Number Publication Date
MX2022007943A true MX2022007943A (es) 2022-07-27

Family

ID=74626080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007943A MX2022007943A (es) 2019-12-27 2020-12-23 Formas farmaceuticas solidas que contienen bacterias y vesiculas extracelulares microbianas.

Country Status (13)

Country Link
US (1) US20230355689A1 (enExample)
EP (1) EP4081195A1 (enExample)
JP (1) JP2023510158A (enExample)
KR (1) KR20220128362A (enExample)
CN (1) CN114945357A (enExample)
AR (1) AR122353A1 (enExample)
AU (1) AU2020413225A1 (enExample)
BR (1) BR112022012514A2 (enExample)
CA (1) CA3165418A1 (enExample)
CO (1) CO2022010242A2 (enExample)
MX (1) MX2022007943A (enExample)
TW (1) TW202135783A (enExample)
WO (1) WO2021133904A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
CN116249540A (zh) * 2020-07-21 2023-06-09 伊夫罗生物科学公司 小韦荣氏球菌菌株作为神经炎性疾病的口服疗法
WO2023049268A1 (en) * 2021-09-24 2023-03-30 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
US20250057893A1 (en) * 2021-12-16 2025-02-20 Enterobiome Inc. Pharmaceutical composition for preventing or treating cancer or inflammatory disease
CN115252651B (zh) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物
KR20250057847A (ko) * 2022-08-29 2025-04-29 일라이 릴리 앤드 캄파니 경구 전달용 조성물
CN116509900B (zh) * 2022-12-01 2023-11-10 佛山科学技术学院 益生菌或其细胞外囊泡在制备防治胃溃疡产品中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775536A (en) 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5292522A (en) 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
EP1101490B1 (en) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
DE19937361A1 (de) * 1999-08-12 2001-02-22 Merck Patent Gmbh Orale Darreichungsform
US20040028737A1 (en) 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
DE10260919A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
CA2543172A1 (en) 2003-10-31 2005-05-19 Dexcel Ltd. Stable lansoprazole formulation
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
CN101209247B (zh) * 2006-12-27 2011-12-14 天津中新药业集团股份有限公司 一种结肠靶向制剂的制备方法
CN101757042A (zh) * 2009-05-25 2010-06-30 北京诚创康韵医药科技有限公司 一种益生菌微丸制剂及其制备
MX2015006491A (es) * 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
CN105142616B (zh) 2013-03-01 2018-02-13 Bpsi控股有限责任公司 含有硅酸钙的延迟释放薄膜包衣及其包被的底物
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN111712260A (zh) * 2018-01-31 2020-09-25 伊夫罗生物科学公司 使用毛螺菌科细菌治疗免疫病症的组合物和方法

Also Published As

Publication number Publication date
AR122353A1 (es) 2022-09-07
EP4081195A1 (en) 2022-11-02
AU2020413225A1 (en) 2022-06-23
TW202135783A (zh) 2021-10-01
US20230355689A1 (en) 2023-11-09
CA3165418A1 (en) 2021-07-01
KR20220128362A (ko) 2022-09-20
CN114945357A (zh) 2022-08-26
WO2021133904A1 (en) 2021-07-01
CO2022010242A2 (es) 2022-10-21
JP2023510158A (ja) 2023-03-13
BR112022012514A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
CO2022010242A2 (es) Formas farmacéuticas sólidas que contienen bacterias y vesículas extracelulares microbianas
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12022550980A1 (en) Small molecule degraders of helios and methods of use
SA519401446B1 (ar) مُعدِّل منظم التوصيل عبر الأغشية للتليف الكيسي، تركيبات صيدلية، طرق علاج، وعملية لتحضير المُعدِّل
MX2022004304A (es) Agentes inductores de apoptosis.
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
WO2018222751A8 (en) Methods for real-time image guided radiation therapy
WO2019084343A8 (en) Peptide compositions and methods of use thereof
MX2019014042A (es) Inhibidores pirazolicos de magl.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
WO2018217710A8 (en) Micro-nanobubble solutions for tissue preservation and generation thereof
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
MX2022000712A (es) Moduladores de nlrp3.
MX2020000693A (es) Compuestos de 1,8-naftiridinona, y usos de los mismos.
WO2021004958A3 (en) Compositions comprising bacterial strains
EP4385529A3 (en) Devices for controlled delivery
MX2026002367A (es) Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso
SG10201803112RA (en) Liquid treatment apparatus
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
WO2022221774A8 (en) Aryl-ring-substituted 3-phenylazetidines and their use in methods for treating 5-ht2 responsive conditions
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020013385A (es) Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion.